adt + arpi

**ADT + ARPi** refers to the combination of **androgen deprivation therapy (ADT)** and an **androgen receptor pathway inhibitor (ARPi)** for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). ADT reduces circulating androgens, thereby slowing the growth of androgen-dependent prostate cancer cells. ARPIs, such as abiraterone, apalutamide, darolutamide, and enzalutamide, further block androgen receptor signaling or androgen synthesis, intensifying inhibition of androgen-driven tumor progression. This combination is associated with prolonged progression-free and overall survival compared to ADT alone, and is considered standard of care for mHSPC[2][3][4].

Other names

ADT + ARPi